Program
IDH1 Inhibitor TQB3454
Also written as “TQB3454 tablets”, “TQB3454 Tablets” and “TQB3454”.
In Sino Biopharmaceutical’s pipeline, IDH1抑制剂
. Its studies are mostly in Leukemia, Myeloid, Acute, led by Sino Biopharmaceutical.
Furthest: phase 3, since Aug 4, 20235 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 54 open or running | phase 3since Aug 4, 2023 | Jul 19, 2020 | Dec 2026phase 3 · NCT05987358 |
- Named in Sino Biopharmaceutical’s own pipeline as
TQB3454
, phase 3, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 19, 2020First study: phase 1 study in Advanced Solid Tumor or Hematologic TumorFirst studyNCT04481607 · 96 enrolled · China
- Aug 4, 2023Phase 3 study in Biliary CarcinomaNCT05987358 · 165 enrolled · China
- Nov 15, 2023Phase 1 study in Biliary CarcinomaNCT06139367 · 40 planned · China
- Jan 12, 2024Phase 2 study in Leukemia, Myeloid, AcuteNCT06218771 · 80 planned · China
- Jul 21, 2026Phase 2 study in Advanced Solid TumorsNCT07738679 · 127 planned · China
Ahead
- Dec 2026Primary completion: phase 3 study in Biliary CarcinomaNCT05987358
- Dec 2028Primary completion: phase 2 study in Advanced Solid TumorsNCT07738679
TargetBeta
“IDH1抑制剂”the company's pipeline, read by Claude · source
“An orally bioavailable, small molecule inhibitor of isocitrate dehydrogenase type 1 (IDH1; IDH-1; IDH1 [NADP+] soluble) mutant forms, ”NCIt, by rule
Other programs on IDH1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| olutasidenibrule | Rigel Pharmaceuticals | phase 4 | 5 |
| ivosidenibrule | Agios Pharmaceuticals | phase 3 | 13 |
| vorasidenibrule | Agios Pharmaceuticals | phase 3 | 12 |
| ranosidenibrule | HUTCHMED | phase 3 | 7 |
| safusidenibrule | Nuvation Bio | phase 3 | 6 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07738679Advanced Solid Tumors · China | 2 | Not yet recruiting | Dec 2028 | 127 |
| NCT06218771Leukemia, Myeloid, Acute · China | 2 | Recruiting | Jun 2025 | 80 |
| NCT06139367Biliary Carcinoma · China | 1 | Not yet recruiting | Dec 2023 | 40 |
| NCT05987358Biliary Carcinoma · China | 3 | Active, not recruiting | Dec 2026 | 165 |
| NCT04481607Advanced Solid Tumor or Hematologic Tumor · China | 1 | UNKNOWN | Dec 31, 2022 | 96 |
How it is read
Names in the registry
- “TQB3454 tablets”, 3 entries
- “TQB3454 Tablets”, 1 entry
- “TQB3454”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.